Pfizer and Arvinas plan vepdegestrant programme expansion after data at SABCS
The companies presented positive Phase Ib data at the 2023 SABCS meeting, and announced plans to expand the protein degrader programme.
cassie WP
Jazz Pharmaceuticals and MD Anderson enter zanidatamab research deal
Cybersecurity in pharma: Q&A with GlobalData thematic analyst
FDA panel says Amgen’s Phase III lung cancer KRAS drug data is unreliable
Janssen’s patient programme becomes latest victim of data breach
FDA issues guidance on using real-world data for drug development
HHS cracks down on hidden insurance fees
MHRA reveals new corporate plan to expedite drug regulatory journeys in UK
